Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading

By person

13 insiders · 12 transactions

0.3×

Julie Eastland holds only 0.3 times base salary in stock. $276.97K of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Julie Eastland last reported holding, valued at $3.50, the price Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Walters Group entity

10% owner

$22.92M (2)

—

+$22.92M

17,844,973

24.90%

$62.46M

+153.1%

Matrix Capital Management Company, LP entity

10% owner

—

$9.98M (1)

−$9.98M

6,459,973

9.01%

$22.61M

−53.7%

Vincent Vultaggio

PAO and PFO

—

$105.43K (5) scheduled

−$105.43K

146,506

0.2044%

$512.77K

+332.7%

Julia Marie Eastland

CEO & President

—

$21.24K (2)

−$21.24K

79,133

0.1104%

$276.97K

—

Ingmar Bruns

Chief Medical Officer

—

$8.00K (2)

−$8.00K

43,059

0.0601%

$150.71K

—

Andrea Paul

Chief Legal Officer

—

1,070,784

1.49%

$3.75M

+614.0%

Mark Lackner

Chief Scientific Officer

—

512,856

0.7156%

$1.79M

+162.0%

Scott Dunseth Myers

Director

—

395,895

0.5524%

$1.39M

—

David Michael Johnson

Director

—

307,521

0.4291%

$1.08M

+59.5%

Jan Skvarka

Director

—

264,254

0.3687%

$924.89K

+195.1%

Luke Nathaniel Walker

Director

—

201,384

0.2810%

$704.84K

+177.8%

Enoch Kariuki

Director

—

194,465

0.2713%

$680.63K

+143.8%

Shannon Campbell

Director

—

114,200

0.1593%

$399.70K

—

Zentalis Pharmaceuticals, Inc.

What the insiders did Net buying

By person